среда, 6 октября 2021 г.

together: “Kahn Swick & Foti, LLC Investigates Adequacy Of Price And Process In Proposed Sale Of Elmira Savings Bank : ESBK” plus 49 more

together: “Kahn Swick & Foti, LLC Investigates Adequacy Of Price And Process In Proposed Sale Of Elmira Savings Bank : ESBK” plus 49 more

Link to together

Kahn Swick & Foti, LLC Investigates Adequacy Of Price And Process In Proposed Sale Of Elmira Savings Bank : ESBK

Posted: 06 Oct 2021 09:00 AM PDT

Now why would ALL of them need to meet over a debt limit

Posted: 06 Oct 2021 09:40 AM PDT

Now why would ALL of them need to meet over a debt limit? https://ift.tt/3muNA3t

Sasol Announces Lead Role In Feasibility Study For The Boegoebaai Green Hydrogen Project

Posted: 06 Oct 2021 09:00 AM PDT

I was the idiot this morning.

Posted: 06 Oct 2021 09:00 AM PDT

https://t.me/enacademicgroup/6618659

Posted: 06 Oct 2021 07:14 AM PDT

translate.deacademic.com › Kasematte

Übersetzungen — kasematte — von deutsch — — 1
Read more...

-- Delivered by Feed43 service

I converted a van into a home and now work remotely and travel full-time.

Posted: 06 Oct 2021 07:43 AM PDT

Brightline Dealer Advisors Launches As Unique One-Stop-Shop For All Automotive Dealers Finance & Insurance, Property & Casualty, And Employee Benefits Needs

Posted: 06 Oct 2021 09:40 AM PDT

Brightline Dealer Advisors Launches As Unique One-Stop-Shop For All Automotive Dealers Finance & Insurance, Property & Casualty, And Employee Benefits Needs…

Worldwide MRNA Industry To 2026 - Key Drivers And Restraints

Posted: 06 Oct 2021 10:15 AM PDT

DUBLIN, Oct. 6, 2021 /PRNewswire/ -- The "mRNA: Therapeutics and Global Markets 2021-2026" report has been added to ResearchAndMarkets.com's offering.

The global market for mRNA therapeutics should grow from $46.7 billion in 2021 to $101.3 billion by 2026, at a compound annual growth rate (CAGR) of 16.8% for the period of 2021-2026.

The U.S. market for mRNA therapeutics should grow from $21.5 billion in 2021 to $46.5 billion by 2026, at a CAGR of 16.7% for the period of 2021-2026.

The Asia-Pacific market for mRNA therapeutics should grow from $6.1 billion in 2021 to $13.8 billion by 2026, at a CAGR of 17.9% for the period of 2021-2026.

Report Includes:

  • 32 data tables and 32 additional tables
  • An overview of the global market for mRNA therapeutics
  • Analyses of global market trends with data from 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
  • Highlights of the major developments, pandemic threats, therapeutic developments, and technological developments of the mRNA therapeutics market
  • Discussion on significant advantages of mRNA over protein or DNA-based delivery systems and description of demographic and economic trends, and outlook of the mRNA therapeutics market
  • Evaluation of current market size and forecast and information on prophylactic vaccines, vaccine discovery and development, and R&D activities
  • Analysis of the various innovative therapeutics as well as new promising vaccines intended for the prevention and treatment of various chronic and infectious diseases
  • Assessment of regulatory structure, pricing and reimbursement scenario, and pipeline analysis of the new molecules & therapeutics
  • Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
  • Comprehensive company profiles of major players of the industry, including Amgen Inc., Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson and Novartis

mRNA therapeutics have emerged as a rapidly growing field with multibillion-dollar business potential within the biotherapeutics market. The therapeutic use of mRNA is unique and powerful since it plays a very critical role in human biology and instruct cells to make proteins to circulate throughout the body.

Recent commercial success has shown its potential to transform the biopharma industry, the same way that the first-generation biotech companies (such as Amgen, Biogen and Genentech) did in the 1980s when they began developing recombinant protein therapies called biologics. The COVID-19 pandemic became the first pandemic of the current generation. It created lots of mRNA buzz in the market in terms of appreciating the bigger picture of the mRNA segment and its wider potential of developing precise and individualized therapies targeting diseases beyond viral infections.

Revenue from 2021 is an estimate based on sales of the first two quarters (Q1 & Q2) along with projections of dose orders for 2021 by leading companies. mRNA therapeutics typically include vaccines, drugs and therapies developed through mRNA technology. This market growth is fueled by the increasing incidence of infectious diseases (e.g., COVID-19, Zika, influenza, Ebola, etc.); increasing prevalence of chronic diseases (e.g., cancer, heart diseases, respiratory, CKD, etc.), rare diseases (e.g., methylmalonic acidemia, propionic acidemia, phenylketonuria, glycogen disease, etc.), and metabolic and immune disorders; commercialization of mRNA vaccines; development of personalized therapeutics for cancer; strong pipeline of therapeutics addressing the unmet need for rare diseases; and growing global acceptance for mRNA therapeutics (e.g., COVID-19, Ebola, influenza, HIV) over traditional drugs and vaccines.

The market for 2020 is relatively lower since BioNTech and Moderna received emergency approvals for their vaccines in December 2020. Additionally, 2021 revenue is also an estimate based on sales of first two quarters (Q1 and Q2) along with projections of doses ordered to be delivered by 2021, by leading companies. The U.S. is expected to maintain dominance in the mRNA therapeutics market. This growth is due to the growing geriatric population, rise of COVID-19 pandemic, increasing incidence of infectious diseases, increasing prevalence of chronic diseases, growing demand for transformative therapeutics, increasing acceptance of mRNA vaccines, preventive care, continuous technological advancements, increasing investment, incentives for new product development, unmet need for rare disease treatment, favorable regulatory environment, acceptance of personalized medicine and increasing adoption of treatment adherence technologies and software applications.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Target Diseases and Disorders

  • Overview of Common Diseases and Disorders for mRNA Therapeutics
  • Cancer
  • Infectious Diseases
  • Cardiovascular Disease
  • Lifestyle Disorders
  • Respiratory Disorders
  • Musculoskeletal Disorders
  • Gastrointestinal Disorders
  • Urology Disorders
  • Nephrology Disorders
  • Immune Disorders
  • Neurological Disorders
  • Rare Diseases
  • Other Disorders
  • Tobacco Smoking and Associated Diseases
  • Infectious Diseases: COVID-19 Pandemic Set the Stage for mRNA Therapeutics
  • Chronic Diseases: Expanding Horizon for mRNA Therapeutics
  • Rare Diseases: Large Unmet Need is Fueling mRNA Therapeutics
  • Ageing, Gender and Onset of Diseases
  • Global Demographics
  • U.S. Demographics
  • European Demographics
  • Japanese Demographics
  • Current Challenges and Future Directions

Chapter 4 RNA Therapeutics

  • RNA Therapeutics Overview
  • Evolution of RNA Therapeutics
  • History of RNA Therapeutics
  • Development of RNA Therapeutics and Types
  • DNA vs. RNA Therapeutics
  • Clinical Need for RNA Therapeutics
  • Increasing Disease Population and Economic Burden
  • Limitations of Traditional Therapeutics
  • Therapeutic Limitations of Biologics
  • Poor Management of Chronic Diseases
  • Limited Treatment for Rare Diseases
  • RNA Therapeutics
  • Antisense Oligonucleotide (ASO) as Therapeutics
  • Small Interfering RNA (siRNA) as Therapeutics
  • miRNA as Therapeutics
  • Aptamers as Therapeutics
  • mRNA as Therapeutics
  • Manufacturing RNA-Based Biopharmaceuticals
  • Chromatographic Purification Steps
  • Delivery of RNA Therapeutics
  • Polymer Conjugation/Chemical Modification
  • Encapsulation
  • Lipid-Based Nanoparticles
  • Polymer Nanomaterials
  • Silica Nanoparticles
  • Carbon and Gold Nanomaterials
  • GalNAc
  • Institution and Hospital-Based RNA Therapeutics
  • Regulatory Influence on the Market for RNA Therapeutics
  • Market Situation for RNA Therapeutics
  • Well-Developed Markets
  • Developing Markets
  • Underdeveloped Markets
  • Therapeutics and Cost Burden
  • Unmet Need
  • Current Challenges and Future Developments

Chapter 5 mRNA Vaccines

  • Vaccines: Overview
  • Vaccine-Based Disease Prevention
  • Evolution of mRNA as Vaccine
  • Clinical Need for mRNA Vaccines
  • mRNA Vaccines and Types by Application
  • Prophylactic/Protective Vaccines
  • Therapeutic Vaccines
  • mRNA Vaccine Product Segments
  • Non-amplifying mRNA Vaccines
  • Self-amplifying mRNA Vaccines
  • Immunogenicity and mRNA Vaccines
  • Optimizing Injection Routes
  • Co-encapsulation of Other Stimulatory Molecules
  • Formulation and Delivery of mRNA Vaccine
  • Approaches for Enhancing mRNA Stability
  • Advantages of mRNA Vaccines
  • Traditional Vaccine vs. mRNA Vaccines
  • Marketed/Commercial mRNA Vaccines
  • Moderna
  • BioNTech
  • mRNA Vaccine Pipeline and New Developments
  • mRNA Vaccine Pipeline by Company
  • mRNA Vaccines: New Developments
  • mRNA Vaccines and Future Pandemics
  • Unmet Need
  • Current Challenges and Future Outlook

Chapter 6 mRNA Drugs and Therapies

  • Overview of Drugs and Therapeutics
  • Therapeutic-Based Disease Treatment
  • Evolution of mRNA: Beyond Vaccines
  • Clinical Need for mRNA Therapeutics Beyond Vaccines
  • mRNA Vaccines vs. mRNA Therapeutics
  • mRNA Therapeutics and Types
  • mRNA as Gene and Protein Replacement Therapy
  • mRNA-Enhanced Cell Therapies
  • mRNA-Enhanced Immunotherapies (Monoclonal Antibody)
  • Advantages mRNA Drugs and Therapies
  • Delivery of mRNA Therapeutics
  • mRNA Therapeutics Pipeline and New Developments
  • mRNA Drugs for Protein Therapy Targeting Metabolic and Rare Diseases
  • Pipeline for mRNA-Therapeutics by Company
  • Pipeline for mRNA-Enhanced Cell Therapies
  • mRNA Therapeutics and New Developments
  • Widespread Concerns over the mRNA Medicinal Industry
  • Issues with Personalized Medicine
  • Unmet Need for mRNA Therapeutics
  • Current Challenges and Future Outlook

Chapter 7 Market Size and Growth Analysis

  • Overview
  • Market Size and Growth Analysis by Region
  • Market Size and Growth Analysis by Product Segment
  • mRNA Vaccines vs. Traditional Vaccines
  • mRNA Drugs and Therapies
  • Market Size and Growth Analysis by Therapeutic Treatment Type
  • Market Size and Growth Analysis by Disease Type
  • Market Growth Drivers and Restraints
  • Market Growth Drivers
  • Market Restraints
  • Regulatory Impact on the Market for mRNA Therapeutics
  • SWOT Analysis of the Market for mRNA Therapeutics

Chapter 8 Competitive Landscape in the Market for mRNA Therapeutics

  • Disease Prevention and Treatment with mRNA Therapeutics

Chapter 9 Strategies in the Market for mRNA Therapeutics

  • Consolidation in the Pharmaceutical Market
  • Mergers and Acquisitions in the Biopharmaceutical Market
  • Recent Strategic Moves in mRNA Therapeutics
  • Key M&A and In-licensing Deals
  • Key Strategic Partnerships
  • Key Venture Financing Deals
  • Future Strategic Landscape

Chapter 10 Regulatory Structure for Biopharmaceuticals

  • Regulatory Background
  • Regulatory Systems for Biopharmaceuticals by Region
  • United States
  • Europe
  • Japan
  • Regulatory Systems for Medical Devices by Region
  • United States
  • European Union
  • Japan
  • Regulations for mRNA Therapeutics
  • Current Regulatory Issues for mRNA Therapeutics
  • Moderna Vaccine Regulation in the U.K.
  • Key Regulatory Updates, 2020
  • Pharmaceuticals
  • Medical Devices

Chapter 11 Pricing and Reimbursement: Pharmaceuticals and Biologics

  • Pricing and Reimbursement Background
  • Pricing and Reimbursement of Pharmaceuticals and Biologics by Region
  • United States
  • Private Health Insurance
  • Chronic Diseases and Cost Burden on Medicare
  • Rise of Infectious Diseases and Pricing & Reimbursement for Vaccines in the US.
  • Europe
  • Japan
  • Pricing and Reimbursement Challenges for Pharmaceuticals
  • Patented Medicines Price
  • Prices of Older Drugs
  • Pricing and Reimbursement for Medical Devices by Region
  • United States
  • Europe
  • Japan
  • Other Parts of Asia-Pacific

Chapter 12 Conclusions on the Outlook for mRNA Therapeutics

  • Major Developments Influencing the Market
  • Digital Transformation and Technological Developments
  • Increasing R&D Spend and Shift Towards Modern Therapeutics and Technologies
  • Collaborations for Advanced Therapeutics
  • Market Consolidation for Strategic Growth and to Retain Market Leadership
  • Demographic and Economic Trends
  • Changing Structure of the Pharma and Healthcare Industry
  • Lifestyle Medicine
  • Patient-Centric Programs
  • Prevalence of Self-Care
  • Burden on Public Health System
  • Long-Term Outlook

Chapter 13 Company Profiles

  • Accurna Inc.
  • Amgen Inc.
  • Arcturus Therapeutics Inc.
  • Argos Therapeutics Inc.
  • Arrowhead Pharmaceuticals
  • Athersys
  • Biocad
  • Biontech
  • Boehringer Ingelheim
  • Cansinobio
  • Cartesian Therapeutics Inc.
  • Chimeron Bio
  • Crispr Therapeutics Inc.
  • Curevac
  • Daiichi Sankyo
  • Eli Lilly And Co.
  • Elixirgen Therapeutics Inc.
  • Etherna Immunotherapies
  • Ethris Gmbh
  • Genentech (Subsidiary Of Roche)
  • Glaxosmithkline Plc
  • Greenlight Biosciences Inc.
  • HDT Bio Corp.
  • In-Cell-Art
  • Intellia Therapeutics
  • Ionis Pharmaceuticals Inc.
  • Johnson & Johnson
  • Kernal Biologics Inc.
  • Maxcyte Inc.
  • Merck Kgaa
  • Mercurna
  • Moderna Therapeutics
  • Novartis
  • Nutcracker Therapeutics
  • Pfizer
  • Phion Therapeutics
  • Poseida Therapeutics Inc.
  • Quark Pharmaceuticals
  • Recode Therapeutics
  • Regulus Therapeutics
  • Rnaimmune Inc.
  • Roche
  • Sangamo Therapeutics Inc.
  • Sanofi
  • Sarepta Therapeutics
  • Shanghai Bendao Gene Technology Co., Ltd.
  • Stemirna Therapeutics Ltd.
  • Strand Therapeutics
  • Tiba Biotechnology Llc
  • Translate Bio
  • Vertex Pharmaceutical

Chapter 14 Appendix A: List of Acronyms

Chapter 15 Appendix B: Professional Organizations

For more information about this report visit https://www.researchandmarkets.com/r/aokzaz

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com    For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

View original content: https://www.prnewswire.com/news-releases/worldwide-mrna-industry-to-2026---key-drivers-and-restraints-301394313.html

SOURCE Research and Markets

https://t.me/enacademicgroup/6618661

Posted: 06 Oct 2021 07:14 AM PDT

Telegram Widget


Read more...

-- Delivered by Feed43 service

USDOT Secretary Buttigieg Joins Roadway Safety Foundation In Honoring Seven Life-Saving Projects With 2021 National Roadway Safety Awards

Posted: 06 Oct 2021 10:11 AM PDT

WASHINGTON, Oct. 6, 2021 /PRNewswire/ -- U.S. Secretary of Transportation Pete Buttigieg, on behalf of the Federal Highway Administration (FHWA), joined the Roadway Safety Foundation (RSF) today in presenting seven life-saving projects with National Roadway Safety Awards in a virtual ceremony hosted from Capitol Hill.

 

Representing some of the very best highway safety practices, the seven winners were selected from a nationwide field of applicants for the awards, which are sponsored jointly by FHWA and RSF. Begun in 1999, the biennial program honors projects and programs that cost-effectively help the nation achieve progress toward eliminating highway fatalities and serious injuries.

"Congratulations to today's seven honorees for the remarkable work they've done to protect the traveling public," said Buttigieg. "They are proof that we have no shortage of willpower or good ideas for improving roadway safety." (Please see accompanying video of Secretary Buttigieg's remarks.)

Preliminary data from the National Highway Traffic Safety Administration  show that 38,680 people died in motor vehicle traffic crashes in 2020 - a 7.2 percent increase from 2019. This increase occurred despite a 13.2 percent decrease in vehicle miles traveled due to the pandemic and is the highest number of fatalities since 2007.

"Projects like these save lives by significantly discouraging dangerous driving," said Greg Cohen, Executive Director of the Roadway Safety Foundation. "Countless future travelers, whose lives and limbs will be spared by these innovations, will owe an unknowing debt of gratitude to today's honorees. We urge DOTs across the nation to look at Bellevue and other awardees' innovations and replicate them wherever possible."

Applicants were encouraged to nominate projects and programs that are innovative, effective and cost efficient. The awards covered two categories: A) Infrastructure and Operational Improvements, and B) Program Planning, Development and Evaluation.

From dozens of entries, a highly credentialed, expert panel of judges selected the seven winners and three honorable mentions. They winners are:

  • Florida Department of Transportation (FDOT) for its use of smart Work Zone Safety Technologies for Arterial Roads, which are burdened with higher fatality rates than interstates. FDOT studied the use of Active Work Zone Awareness Devices (AWADs), which employ radar in combination with LED signs to warn drivers of upcoming work zones, displays their travel speed and delivers safety messaging. FDOT went a step further by linking the AWADs to drivers using the Waze navigation app. The initiative's impressive results include vehicle speeds entering arterial work zones dropping by 10.6 percent, safe driving behavior increasing by 39 percent, and risky driving declining by 34 percent.
  • North Carolina Department of Transportation (NCDOT) for its Long-Life Pavement Markings Safety Initiativeto reduce lane departure crashes, a major safety challenge in a state where 14,000 fatal and serious-injury lane departure crashes occurred between 2015 and 2019. Designed to help drivers better see markings when driving on curvy roads, in inclement weather or at night, NCDOT tested the long-life markings on more than 400 miles of roadway, recording an overall 13 percent reduction in lane departure crashes. The long-life markings also are designed to provide at least five to seven years of adequate retro-reflectivity and pavement delineation, as compared with approximately two years from standard markings, thereby being more cost efficient in the long term.
  • Village of Whitefish Bay, WI for its Community-Wide Safety Improvements. Confronting a decade-long increase in crashes involving the most vulnerable road users, the Milwaukee suburb deployed a series of low-cost solutions to reduce risks to pedestrians and cyclists. These included dynamic speed feedback signs, "yield to pedestrian" signage, design changes such as high-visibility crosswalks, installation of median in the center of highways, lengthier pedestrian intervals at signals and better street lighting. A simple but noteworthy improvement is the installation of "Danish Offsets." Widely deployed in Denmark, crosswalk paths are oriented to provide more direct sight lines for pedestrians to observe oncoming vehicles. Since 2015, community-wide crashes are down 39 percent and signs point to a continued downward trend.
  • City of Bellevue, WA for its application of a Video Analytics Program that is helping achieve tangible progress toward the city's Vision Zero commitment. Prevailing practice in highway safety management typically relies on backward-looking crash data, an inherently reactive process. By contrast, Bellevue is utilizing cutting-edge video analytics to identify safety challenges in near-real-time, enabling the city to proactively address those challenges. The smart technologies convert raw video from existing traffic cams into flow, speed and conflict event data. In addition to identifying hot spots, Bellevue's video analytics program also provides rapid insight on how countermeasures perform. As just one example, Bellevue made traffic signal operations changes at 124 th Avenue Northeast and Northeast Eighth Street and observed a 60 percent reduction in critical conflicts at the intersection.
  • Broward Metropolitan Planning Organization for its innovative Complete Streets Master Plan, which is measurably improving safety on Wilton Drive in the Fort Lauderdale area and promises similar benefits on other local roadways. With the single highest number of pedestrian fatalities in the entire nation (1,675 between 2010 and 2019), Broward worked with localities and other stakeholders to redesign the bustling Wilton Drive, eliminating a vehicular travel lane in each direction in order to install buffered bike lanes, mid-block crossing medians, wider sidewalks, better lighting and other improvements. Witnessing a 66 percent decrease in bicycle and pedestrian crashes and a 75 percent reduction in severe-injury and fatal crashes - alongside a 50 percent improvement in corridor travel times - Broward is moving forward with similar improvements for 20 other projects.
  • California Department of Transportation (Caltrans) for its transformative 2020-2024 Strategic Highway Safety Plan (SHSP) to reverse a trend of rising fatalities and injuries on state roads. With an average of 10 people dying every day on California roads, Caltrans created a highly targeted approach to safety with its SHSP update. It designates high-priority challenge areas, expands and diversifies membership of the SHSP committee, implements the program with innovative tools, and evaluates progress on a continual basis. Four newly adopted guiding principles undergird the SHSP: Integrate equity, implement a safe system approach, double down on what works, and accelerate advanced technology. The plan is instrumental to the state achieve no traffic fatalities and serious injuries by 2050.
  • Texas Department of Transportation (TxDOT) and Texas A&M Transportation Institute (TTI) for its all-new Safety Scoring Tool. With fatalities on Texas rural non-interstate roads occurring at twice the rate of other Texas roads, TxDOT partnered with the Texas A&M Transportation Institute to develop a user-friendly means of evaluating the safety performance of rural highway design elements. The scoring tool assesses the total effects of changes in lane and shoulder width, horizontal and vertical curve geometry, clearances to objects, and other factors. The tool is now required for all rural two and multi-lane non-access controlled projects, ranging from routine maintenance to complete reconstructions, fostering a proactive, rather than passive or reactive, approach to safety.

The honorable mentions are: The Florida Department of Transportationfor its Local Technical Assistance Program to improve the skills and increase the knowledge of the transportation workforce on roadway safety via virtual training and technical assistance; the Montana Department of Transportationfor its reconstruction of an antiquated segment of U.S. Highway 89 that provides a key entrance to Glacier National Park; and the Town of Portland, Ct. for its formation of a grassroots Complete Streets Group to coordinate with local officials in writing, adopting, and implementing a Complete Streets Policy. 

Winners were selected by an expert panel of judges from a variety of disciplines. For complete details on each of the winners, and for more information on the national awards program, visit roadwaysafety.org/awards.

The Roadway Safety Foundation is a 501(c) (3) charitable and educational organization. Our mission is to reduce the frequency and severity of motor vehicle crashes, injuries, and fatalities through improvements to roadway systems and their environment.

View original content to download multimedia: https://www.prnewswire.com/news-releases/usdot-secretary-buttigieg-joins-roadway-safety-foundation-in-honoring-seven-life-saving-projects-with-2021-national-roadway-safety-awards-301394422.html

SOURCE Roadway Safety Foundation

Перевод: с китайского на все языки

Posted: 06 Oct 2021 10:21 AM PDT

beanstanden

Posted: 06 Oct 2021 10:21 AM PDT

https://t.me/enacademicgroup/6618674

Posted: 06 Oct 2021 07:14 AM PDT

Русский: *translate.deacademic.com " Карбюратор*

Переводы - карбюратор - с немецкого - - 1
[Read more...](https://translate.deacademic.com/Vergaser/de/)

-- Delivered by Feed43 service

Древний красивый обычай

Posted: 06 Oct 2021 10:29 AM PDT

https://www.rbc.ru/rbcfreenews/615daacb9a7947e811106211

Брать заложников человек разумный научился в глубокой древности. При дворах властителей воспитывались дети их вассалов или союзников. Даже встреча двух предводителей воюющих войск могла произойти на территории одного из них лишь после того, как во вражеское войско на время переговоров отправляли в качестве заложников десятки высших офицеров.
Террористы вывели идею захвата заложников на новый уровень. Правительство сразу оказывается в цугцванге: пойдешь на сделку с террористами — потеряешь поддержку населения, не пойдешь, заложники погибнут, потеряешь поддержку населения.
И вот новая реинкарнация древней людской забавы — государство само берет в заложники одних граждан, желая добиться покорности от других.

На этот раз в заложники взят муж сбежавшей Раковой. Сильно ли я им обоим сочувствую? Да нет, не буду врать. Вовсе не сочувствую. Но захват заложников это же всегда яркое зрелище и прямые эфиры в самое рейтинговое время? Можно пари принимать — подействует арест мужа на Ракову, или "Я выбираю свободу!"

Написал Ленивый Portal на polka.d3.ru / комментировать

• • •

Posted: 06 Oct 2021 10:29 AM PDT

Unexpected departure
Paul Bond, 2006

Написал gvachparadox на blue.d3.ru / комментировать

Перевод: с английского на все языки

Posted: 06 Oct 2021 10:21 AM PDT

https://t.me/enacademicgroup/6618660

Posted: 06 Oct 2021 07:14 AM PDT

*Telegram Widget*


[Read more...](/channel/enacademicgroup/6618605?embed=1)

-- Delivered by Feed43 service

Kawasaki Engines To Showcase Engines, Parts And Accessories At GIE EXPO 2021

Posted: 06 Oct 2021 09:40 AM PDT

Kawasaki Engines To Showcase Engines, Parts And Accessories At GIE EXPO 2021 https://ift.tt/3iF0T0d

Now why would ALL of them need to meet over a debt limit?

Posted: 06 Oct 2021 09:01 AM PDT

https://t.me/enacademicgroup/6618662

Posted: 06 Oct 2021 07:14 AM PDT

Русский: *translate.deacademic.com " Каземат*

Переводы - каземат - с немецкого — - 1
[Read more...](http://translate.deacademic.com/Kasematte/de/)

-- Delivered by Feed43 service

Enacademic

Posted: 06 Oct 2021 09:01 AM PDT

ARK Investment Management LLC Announces Relocation Of Its Corporate Headquarters And Groundbreaking For The ARK Innovation Center

Posted: 06 Oct 2021 09:00 AM PDT

Telegram Widget

Posted: 06 Oct 2021 08:32 AM PDT

New Bite Block Aims To Improve Oxygenation During GI Procedures

Posted: 06 Oct 2021 10:16 AM PDT

ANN ARBOR, Mich., Oct. 6, 2021 /PRNewswire/ -- Micro-Tech Endoscopy USA seeks to improve oxygenation during endoscopic procedures with its newest invention, Breathe-EZ Bite Block.

The Breathe-EZ Bite Block was designed with a softer bite plate that helps keep the lower jaw forward and airway open.

Bite blocks offer comfort, protection and assistance during upper endoscopic procedures. The new Breathe-EZ Bite Block was designed with a special, softer bite plate that helps to keep the lower jaw forward and the airway open. Breathe-EZ compliments Micro-Tech's existing portfolio of bite blocks by offering a composition made with the same premium materials but with a unique and enhanced design.

"Physicians rely heavily on the clinical staff to maintain an open airway through a head tilt and manual jaw thrust maneuver when respiratory complications arise during endoscopic procedures," explained Micro-Tech USA Executive Global R&D Director Scott Haack. "Breathe-EZ inherently opens a patients airway by keeping the lower jaw in a fixed forward position without constant hands-on care by the staff."

Since 2000, Micro-Tech has been focused on creating top-quality products for endoscopic diagnosis and therapeutic medical devices that allow physicians to provide the highest level of care. By partnering with doctors dedicated to innovation, we are committed to bringing better devices to market, with unprecedented speed, at an economical price, and without the burden of contracts. We do not compromise on quality and do not believe our customers should either.

Micro-Tech Endoscopy has operations in America, Asia, and Europe and leverages this global reach to refine the products we provide to our partners. Our team has a wealth of experience in the field and an in-depth understanding of both product and use cases.

With the health care industry transforming rapidly, we dedicate ourselves to set the pace as a disruptor. At Micro-Tech, we are more than a medical technology company - we are building a community of healthcare innovators and making health care more value-driven.

View original content to download multimedia: https://www.prnewswire.com/news-releases/new-bite-block-aims-to-improve-oxygenation-during-gi-procedures-301394425.html

SOURCE Micro-Tech Endoscopy

Перевод: с казахского на русский

Posted: 06 Oct 2021 10:18 AM PDT

academic2.ru

Posted: 06 Oct 2021 08:32 AM PDT

ADHD student watching two 10 min. video

Posted: 06 Oct 2021 08:32 AM PDT

https://t.me/enacademicgroup/6618675

Posted: 06 Oct 2021 07:14 AM PDT

English: translate.deacademic.com " Carburetors

Translations - carburetor - from english - - 1
Read more...

-- Delivered by Feed43 service

FDA Revises Hospital And Health System Compounding Guidance To Help Preserve Patient Access To Compounded Drugs

Posted: 06 Oct 2021 09:01 AM PDT

*translate

Posted: 06 Oct 2021 07:58 AM PDT

*translate.deacademic.com › Kasematte*

Übersetzungen — kasematte — von deutsch — — 1
[Read more...](http://translate.deacademic.com/Kasematte/de/)

The Cuckoo Clock of Doom - Academic Dictionaries and ...

Posted: 06 Oct 2021 10:21 AM PDT

Мадонна

Posted: 06 Oct 2021 10:29 AM PDT

sinonimos.esacademic.com › humilde

Posted: 06 Oct 2021 10:21 AM PDT

adjetivo 1) dócil, obediente, sumiso. ≠ soberbio. Tratándose del carácter, actitud o comportamiento de una persona: es una persona muy humilde.

Adidas выпустит ограниченным тиражом кроссовки в честь 20-летия Xbox

Posted: 06 Oct 2021 10:20 AM PDT

Команда Xbox совместно с брендом спортивной одежды Adidas создают кроссовки, посвящённые 20-летию первой игровой консоли компании Microsoft. Напомним, оригинальная Xbox дебютировала в США 15 ноября 2001 года. Кроссовки, которые выйдут ограниченным тиражом, будут украшены логотипом Xbox и декоративными полупрозрачными элементами зелёного цвета. theverge.com

Intel Core i7-12700K оказался быстрее Ryzen 9 5900X в приложениях Adobe Photoshop и After Effects

Posted: 06 Oct 2021 09:00 AM PDT

nominale

Posted: 06 Oct 2021 10:21 AM PDT

Ελλάδα - Αθλητισμός - Dictionary of Greek

Posted: 06 Oct 2021 10:21 AM PDT

https://t.me/enacademicgroup/6618677

Posted: 06 Oct 2021 07:14 AM PDT

العربية: translate.deacademic.com " المكربن

Translations-carburetor-من الإنجليزية - - 1
قراءة المزيد...

-- Delivered by Feed43 service

Водка CORN, 40%

Posted: 06 Oct 2021 08:32 AM PDT

[Read more

Posted: 06 Oct 2021 09:40 AM PDT

** [Read more https://ift.tt/3DfIXRr

Zerlegung

Posted: 06 Oct 2021 10:21 AM PDT

Telegram Widget

Posted: 06 Oct 2021 09:40 AM PDT

Telegram Widget https://ift.tt/3FktwJH

https://t.me/enacademicgroup/6618672

Posted: 06 Oct 2021 07:14 AM PDT

translate.deacademic.com › Vergaser

Übersetzungen — vergaser — von deutsch — — 1
Read more...

-- Delivered by Feed43 service

Nokia T20 is a $250 Android tablet with a 10.4 inch display and 3 years of security updates

Posted: 06 Oct 2021 08:32 AM PDT

Перевод: с русского на все языки

Posted: 06 Oct 2021 10:21 AM PDT

General Mills Becomes First U.S. Investment Grade Consumer Packaged Goods Company To Execute A Sustainability-Linked Bond

Posted: 06 Oct 2021 09:01 AM PDT

MSU Health Care Launches Clinician-led Remote Monitoring Services To Patients Across The State

Posted: 06 Oct 2021 09:01 AM PDT

Kawasaki Engines To Showcase Engines, Parts And Accessories At GIE EXPO 2021

Posted: 06 Oct 2021 09:01 AM PDT

translate.esacademic.com › Nechí

Posted: 06 Oct 2021 07:47 AM PDT

См. также в других словарях: Nechí — Bandera … Wikipedia Español. Nechí — Municipality and town Location of the municipality and town of Nechí in the ...

https://t.me/enacademicgroup/6618663

Posted: 06 Oct 2021 07:14 AM PDT

Русский: translate.deacademic.com " Каземат

Переводы - каземат - с немецкого — - 1
Read more...

-- Delivered by Feed43 service

Комментариев нет:

Отправить комментарий

webmention

Infocourt

News digest

Together digest